Number of the records: 1
agonisty vápnikových kanálov
SYS d002120 LBL 00000cz--a2200000n--4500 005 20250606214119.4 008 920323|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 $a BA006 $a BA006 065 $a D27.505.519.562.124 065 $a D27.505.696.260.250 065 $a D27.505.954.411.793.205 066 $a 01 $c 03 150 $a agonisty vápnikových kanálov $x AD $x AE $x AN $x BL $x CF $x CH $x CL $x CS $x EC $x HI $x IM $x IP $x ME $x PD $x PK $x PO $x RE $x SD $x ST $x TO $x TU $x UR $2 slo 450 $w v $a Calcium Channel Activators $2 eng 450 $w v $a Calcium Channel Agonists, Exogenous $2 eng 450 $w v $a agonisty kalciových kanálov $2 slo 450 $w v $a aktivátory kalciových kanálov $2 slo 450 $w v $a agonisty kalciových kanálov, exogénne $2 slo 550 $7 sllk_us_auth*d015220 $Y Calcium Channels $w b $a kanály vápnikové 665 $a 88 $2 eng 665 $a Calcium/metab (1966-1987) $2 eng 665 $a Ion Channels (1979-1987) $2 eng 680 9-
$i Agents that increase calcium influx into calcium channels of excitable tissues. This causes vasoconstriction in VASCULAR SMOOTH MUSCLE and/or CARDIAC MUSCLE cells as well as stimulation of insulin release from pancreatic islets. Therefore, tissue-selective calcium agonists have the potential to combat cardiac failure and endocrinological disorders. They have been used primarily in experimental studies in cell and tissue culture. $2 eng 750 -2
$a Calcium Channel Agonists $2 eng 980 $x M
Number of the records: 1